on behalf of the SAA-WP EBMT Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex vivo T-cell-depleted and unmanipulated grafts have been explored in children and adults. Overall, the primary objective of a stable haploidentical hematopoietic engraftment with a low rate of GVHD is unmet in a significant proportion of patients undergoing haplo-SCT for SAA. Haploidentical transplants for refractory SAA should be performed in a specialist center with major experience in hematopoietic SCT procedures and preferably performed within the framework of a local clinical protocol designed specifically to address the prevention of graft rejection and GVHD.
The great interest in transplantation from haploidentical donors arises from the immediate availability of a suitable one-haplotype mismatched donor for virtually all patients within the appropriate time-frame. In the absence of a fully HLA-matched donor, alternative donors such as cord blood or haploidentical ones have been intensively investigated in the past decade.
1,2 The most common transplantation platform has been the T-celldepleted grafts with a high cell dose of CD34 þ cells obtained from family haploidentical donors. 3 Progress has been made in the optimization of conditioning regimens and graft selection to allow stable hematopoietic engraftment across major HLA barriers, with promising disease-free survival rates in adults with acute leukemias. 2 Unfortunately, transplant-related deaths are observed in a significant proportion of recipients. The leading causes of the deaths reported are infections and interstitial pneumonia.
Several cell therapy strategies are currently being explored to improve post-transplant immune reconstitution while controlling GVHD. [4] [5] [6] A partial T-cell depletion can be provided by alternative selections, such as CD3/CD19 negative selection or selective depletion of alloreactive T-cells; 7 a T-cell content of 1 Â 10 5 /kg in the graft requires a post-transplant immune prophylaxis and translates into a significant risk of acute GVHD.
Recently, new platforms for haploidentical transplantation from unmanipulated grafts have been developed. Huang et al. [8] [9] [10] experienced in large series a GVHD modulation mediated by G-CSF priming of T-cells in the BM and peripheral blood, antithymocyte globulin in the conditioning and a powerful posttransplantation GVHD prophylaxis. Clinical trials based on post-BMT CY targeting activated donor or host alloreactive T-cells have been developed in Baltimore and Seattle. 11, 12 Peccatori et al. Haploidentical transplants have been sporadically carried out in the setting of acquired aplastic anemia in patients failing immune suppressive therapy and lacking an HLA-matched related or unrelated donor. 15, 16 A report on 31 patients from Seattle indicated that unmanipulated marrow transplants from related donors mismatched for one or more HLA loci required an intensive conditioning regimen, containing full-dose TBI, to achieve sustained engraftment. 17 The EBMT SAA Working Party collected 20 patients allografted with unmanipulated marrow from a 41-antigen mismatched related donor; the probability of graft failure at 100 days was 25% and OS at 5 years was 30%. 18 One pediatric patient successfully received a BM graft from her HLA-haploidentical sister after a new conditioning regimen aiming to maximize immunosuppression and minimize toxicity, consisting of Campath-1G or -1H (Alemtuzumab, Genzyme, Cambridge, MD, USA), CY and low-dose TBI. 19, 20 An intense conditioning regimen of CY 200 mg/kg and TBI 800 cGy was investigated in Taiwan in marrow grafting from HLA-haploidentical family donors. Engraftment was documented in all the six patients. Four patients (66.7%) have been alive and disease-free for 8-47 months after BMT. Recently, Xu et al. 21 reported on 19 consecutive severe aplastic anemia (SAA) patients who received a combination of G-CSF-primed BM and G-CSF-mobilized PBSC from haploidentical family donors. All the 19 cases were heavily transfused prior to transplantation. The conditioning regimen prior to hematopoietic SCT (HSCT) included BU, CY and thymoglobulin. The recipients received CsA, mycophenolate mofetil and short-term MTX for GVHD prophylaxis. All the patients achieved 100% donor myeloid engraftment; the median time for myeloid and platelet engraftment was 12 days and 18 days, respectively. The factors that promoted full engraftment in this trial were the intensified conditioning regimen that adds BU to CTX þ antithymocyte globulin, the combination of G-CSF-stimulated BM and G-CSFstimulated peripheral blood grafts that work synergistically to enhance engraftment, and the employment of a potent GVHD prophylactic regimen using CsA, MTX and mycophenolate mofetil. The OS was 64% with a median 746 days follow-up for surviving patients. However, the reported chronic GVHD incidence was 56%. These limited data suggest that HLA-haploidentical HSCT for SAA patients without an HLA-identical sibling donor might be feasible. Further research to increase the OS by decreasing GVHD while maintaining stable engraftment will be needed in the future. The major limitation of this analysis is that 15 out of 19 cases of this series received HSCT as upfront therapy after failing CsA treatment without antithymocyte globulin. Prior to the widespread adoption of this strategy as an upfront or salvage treatment for SAA patients failing immune suppressive therapy, these results need to be validated in a larger cohort. Moreover, further improvement in decreasing GVHD while maintaining a stable engraftment will be needed.
The majority of reports of T-cell-depleted strategy involved purified CD34 þ cells to prevent fatal GVHD (positive selection). The feasibility of large numbers of highly purified haploidentical CD34 þ cells after immunoablative conditioning was assessed in three pediatric patients 22 and in one adult; 23 one patient rejected the first infusion, but was engrafted after a second infusion from the same donor and died 4 months after hematopoietic SCT with no evidence of lymphoid reconstitution. Three patients survived more than 1 year after transplantation with normal blood counts, 100% donor engraftment, effective lymphoid reconstitution and no chronic GVHD.
In a prospective trial, Kyung-Nam Koh et al. 24 explored CD3-or CD3/CD19-depleted grafts instead of purified CD34 þ cells to reduce the risk of severe GVHD and facilitate engraftment by selectively removing T-cells and repleting non-CD34 þ cells (negative selection). A fludarabine-based regimen with dosereduced CY and rabbit-antithymocyte globulin without TBI was used as conditioning in four patients. Total infused CD34 þ cells were in the range of 3-5 Â 10 6 /kg of recipient weight. T-cell depletion was variably effective, with 1-3 log reduction. In terms of CD3 þ cells, two grafts contained 15 and 19 Â 10 4 /kg, while the remaining three grafts contained unexpectedly high doses of 125, 155 and 795 Â 10 4 /kg, respectively. All the patients achieved rapid neutrophil and platelet engraftment, two achieved sustained engraftment with full donor chimerism and remained transfusionindependent, while two developed secondary graft failure or poor graft function; no patients developed clinically significant acute or chronic GVHD. Cotransplantation of MSCs to enhance engraftment is of interest and may be studied in the setting of T-cell-depleted haplo-SCT. 25 A survey based on EBMT ProMISe data, to sort out the current practice better, is ongoing within the SAA-WP. A series of 82 haploidentical transplants in 73 patients have been identified in the period 1977-2011 and will be retrospectively analyzed.
In conclusion, haploidentical HSCT should be considered in patients with SAA failing at least one course of immune suppressive therapy and lacking an HLA-matched related or unrelated donor. At present, there are insufficient data to make a definite recommendation regarding graft composition and conditioning regimen in the setting of haploidentical HSCT for SAA. Both the platforms of ex vivo T-cell-depleted and unmanipulated grafts have been explored; overall results show comparable efficacy and acceptable toxicities of these procedures and therefore are insufficient to indicate which one is superior. In this well-defined clinical indication, the number of patients will be low and therefore randomized studies comparing optional approaches such as T-cell-depleted or unmanipulated grafts are difficult to perform. Our current interpretation of the existing data supports the fact that haploidentical transplants for refractory SAA should be performed in a specialist center with major experience in HSCT procedures, with an appropriate infrastructure as defined by EBMT guidelines and optimally meeting JACIE standards. These transplants should be preferentially performed within the framework of a local clinical protocol designed specifically to address the primary objectives of a stable haploidentical hematopoietic engraftment at a low GVHD rate.
